Brexit: Pharmacovigilance Requirements for UK MAHs

Following the Brexit, the MHRA posted an updated guidance to become familiar with the pharmacovigilance requirements for UK marketing authorization holders (MAHs).

MHRA´s guidance on UK pharmacovigilance requirements  

In the blog post, the agency provides sources of guidance and further information, including the following:

  • In general, the EU Good Pharmacovigilance Practices (GVP, EudraLex Volume 9) continues to apply in the UK.
  • There are some exceptions and modifications to the EU GVP that apply to UK MAHs and the MHRA.
  • Guidance on the submission of the summary of pharmacovigilance system details and on the UK QPPV and the pharmacovigilance system master file (PSMF).
  • Guidance on Pharmacovigilance procedures (e.g. submission of adverse drug reactions reports and PSURs).
  • Frequently asked questions (available by contacting the respective pharmaceutical trade association via Email).

For more information please read the post Guidance on pharmacovigilance requirements for UK authorized products from 1 January 2021 on the MHRA blog.

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK